Publicación:
First Report of OXA-181-Producing Enterobacterales Isolates in Latin America

dc.contributor.authorCuicapuza Arteaga, Diego Bernhard
dc.contributor.authorAlvarado, Luis
dc.contributor.authorTocasca, Norah
dc.contributor.authorAguilar, Daniel
dc.contributor.authorGómez-de-la-Torre, Juan Carlos
dc.contributor.authorSalvatierra Rodríguez, Guillermo Santos
dc.contributor.authorTsukayama Cisneros, Pablo
dc.contributor.authorTamariz Ortiz, Jesús Humberto
dc.coverage.spatialLima, Perú
dc.date.accessioned2026-04-28T22:48:52Z
dc.date.issued2023
dc.description.abstractWe characterized five carbapenemase-producing <i>Enterobacterales</i> (CPE) isolates from two health care institutions in Lima, Peru. The isolates were identified as Klebsiella pneumoniae (<i>n</i> = 3), Citrobacter portucalensis (<i>n</i> = 1), and Escherichia coli (<i>n</i> = 1). All were identified as <i>bla</i><sub>OXA-48</sub>-like gene carriers using conventional PCR. Whole-genome sequencing found the presence of the <i>bla</i><sub>OXA-181</sub> gene as the only carbapenemase gene in all isolates. Genes associated with resistance to aminoglycosides, quinolones, amphenicols, fosfomycins, macrolides, tetracyclines, sulfonamides, and trimethoprim were also found. The plasmid incompatibility group IncX3 was identified in all genomes in a truncated Tn<i>6361</i> transposon flanked by ΔIS<i>26</i> insertion sequences. The <i>qnrS1</i> gene was also found downstream of <i>bla</i><sub>OXA-181</sub>, conferring fluoroquinolone resistance to all isolates. CPE isolates harboring <i>bla</i><sub>OXA</sub>-like genes are an increasing public health problem in health care settings worldwide. The IncX3 plasmid is involved in the worldwide dissemination of <i>bla</i><sub>OXA-181</sub>, and its presence in these CPE isolates suggests the wide dissemination of <i>bla</i><sub>OXA-181</sub> in Peru. <b>IMPORTANCE</b> Reports of carbapenemase-producing <i>Enterobacterales</i> (CPE) isolates are increasing worldwide. Accurate detection of the β-lactamase OXA-181 (a variant of OXA-48) is important to initiate therapy and preventive measures in the clinic. OXA-181 has been described in CPE isolates in many countries, often associated with nosocomial outbreaks. However, the circulation of this carbapenemase has yet to be reported in Peru. Here, we report the detection of five multidrug-resistant CPE clinical isolates harboring <i>bla</i><sub>OXA-181</sub> in the IncX3-type plasmid, a potential driver of dissemination in Peru.en_US
dc.identifier.doihttps://doi.org/10.1128/spectrum.04584-22
dc.identifier.scopus2-s2.0-85163913583
dc.identifier.urihttps://hdl.handle.net/20.500.12866/19205
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofurn:issn:2165-0497
dc.relation.ispartofseriesMicrobiology Spectrum
dc.relation.issn2165-0497
dc.rightshttp://purl.org/coar/access_right/c_14cb
dc.subjectblaOXA-181en_US
dc.subjectcarbapenemase-producing Enterobacteralesen_US
dc.subjectIncX3 plasmiden_US
dc.subjectPeruen_US
dc.subjectcarbapenemase-producing Enterobacteriaceaeen_US
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#1.06.01
dc.titleFirst Report of OXA-181-Producing Enterobacterales Isolates in Latin Americaen_US
dc.typeinfo:eu-repo/semantics/article
dc.type.localArtículo de revista
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos